Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026 (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

October 27, 2025

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2025 Oct 27;67(1740):e178-80 doi:10.58347/tml.2025.1740d

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the 2025-2026 recommendations for treatment and prophylaxis of seasonal influenza.
Compare the antiviral drugs available for treatment of influenza based on their efficacy, dosage and administration, and potential adverse effects.
Determine the most appropriate regimen for treatment or prophylaxis of influenza in a particular patient.

Select a term to see related articles antiviral drugs baloxavir influenza oseltamivir peramivir Rapivab Relenza Tamiflu Xofluza zanamivir

View the Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.